Santhera Pharmaceuticals announces that AGAMREE (vamorolone) has been approved in the United Kingdom (UK) for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older, independent of the underlying mutation and ambulatory status.
The UK’s MHRA, adopting the view of the European Medicines Agency (EMA), acknowledged clinically important safety benefits of AGAMREE with regards to maintaining normal bone metabolism, density and growth compared with standard of care corticosteroids, alongside similar efficacy.
“We are delighted to have secured a third approval for AGAMREE to treat Duchenne from a major regulatory agency, after the US FDA and the EU EMA, within a couple months,” said Shabir Hasham, MD, Chief Medical Officer of Santhera.
“In addition to its anti-inflammatory efficacy, both the EMA and the MHRA recognise the benefits of treatment with AGAMREE for bone health and growth, underlining the favourable safety and tolerability profile of this novel medicine compared with conventional corticosteroids."
"We are working towards making AGAMREE available to patients in the UK in the second half of 2024, after NICE completes its pricing review. Initial European launch will be in Germany in Q1.”
The approval by the EC was based on data from the positive pivotal VISION-DMD study and three open-label studies in which vamorolone was administered at doses between 2 and 6 mg/kg/day for a total treatment period of up to 30 months.
In the pivotal VISION-DMD study, boys treated with vamorolone on average maintained growth similar to those treated with a placebo, whilst those treated with prednisone on average experienced growth stunting.
Patients who switched from prednisone to vamorolone after 24-weeks were, on average, able to resume growing in height during the remainder of the study.
Unlike corticosteroids, vamorolone did not result in a reduction of bone metabolism as measured by bone biomarkers, nor in a significant reduction of bone mineralisation in the spine as measured by Dual Energy X-Ray Absorptiometry (DXA) after 48 weeks in the clinical studies.
In addition, patients who switched from a standard of care corticosteroid to AGAMREE maintained the efficacy benefit while recovering their growth and bone health.
Santhera will continue to collect data to further characterise the long-term effectiveness and the broader safety differentiation of vamorolone.
